IP Library Granted Patent US 12,503,681
Granted Patent B2
US 12,503,681 · App. 18/410,607 · Granted Dec 23, 2025

Systems and methods for bioprocessing

Inventors: Weston Blaine Griffin (Niskayuna, NY); Alex D Corwin (Niskayuna, NY); Xiaohua Zhang (Niskayuna, NY); Reginald Donovan Smith (Niskayuna, NY); Zhen Liu (Niskayuna, NY); Chengkun Zhang (Niskayuna, NY); Vandana Keskar (Niskayuna, NY); Brian Michael Davis (Niskayuna, NY); Kashan Shaikh (Niskayuna, NY)
Assignee: Global Life Sciences Solutions USA LLC
C12M33/14C12M23/24C12M25/02C12M29/10C12M41/44C12M47/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,503,681
App. No.
18/410,607
Granted
Dec 23, 2025
Kind
B2
Abstract

A bioprocessing system includes a first module configured for enriching and isolating a population of cells, a second module configured for activating, genetically modifying, and expanding the population of cells, and a third module configured for harvesting the expanded population of cells.

Claims (17)

1 . A bioprocessing system, comprising: a first module configured for enriching and isolating a first population of cells; a second module configured for activating, genetically modifying, and expanding the first population of cells; and a third module configured for harvesting the expanded first population of cells; wherein the first module is configured for enriching a second population of cells while the second module is carrying out activation, genetic modification, and/or expansion on the first population of cells.

2 . The bioprocessing system of claim 1 , wherein: the second module contains a bioreactor vessel configured to provide for the genetic modification and expansion of the population of cells without removal of the population of cells from the bioreactor vessel, or the second module contains a bioreactor vessel configured to provide for the activation, genetic modification and expansion of the population of cells without removal of the population of cells from the bioreactor vessel.

3 . The bioprocessing system of claim 1 , wherein: the second module includes a first bioreactor vessel and a second bioreactor vessel fluidly interconnected with the first bioreactor vessel.

4 . The bioprocessing system of claim 3 , wherein: the first bioreactor vessel is configured for carrying out activation and genetic modification of the population of cells; wherein the second bioreactor vessel is configured for carrying out expansion of the population of cells.

5 . The bioprocessing system of claim 4 , wherein the bioprocessing system is configured to effect activation and genetic modification of the cells in the first bioreactor vessel, transfer of the cells from the first bioreactor vessel to the second bioreactor vessel, and expansion of the cells in the second bioreactor vessel in an autonomous manner.

6 . The bioprocessing system of claim 3 , wherein: the first bioreactor vessel is configured for performing activation of the population of cells; and the second bioreactor vessel is configured for performing genetic modification and expansion of the population of cells.

7 . The bioprocessing system of claim 1 , wherein at least one of the first module, second module, and/or third module includes a bioreactor vessel configured for filterless perfusion.

8 . The bioprocessing system of claim 1 , wherein: the population of cells is a first population of cells; and wherein the bioprocessing system is configured to support activation, genetic modification and expansion of the first population of cells in the second module simultaneously with enrichment and isolation of a second population of cells in the first module, wherein the first population of cells is different from the second population of cells.

9 . The bioprocessing system of claim 1 , further comprising: a plurality of second modules, each second module configured for activating, genetically modifying and expanding the cells; wherein each second module is configured to support activation, genetic modification and expansion of different populations of cells in parallel.

10 . The bioprocessing system of claim 9 , wherein: the first module is configured for enrichment and isolation of each different population of cells prior to transfer to one of the plurality of second modules for activation, genetic modification and expansion.

11 . The bioprocessing system of claim 10 , wherein: the bioprocessing system is configured to perform enrichment and isolation of one of the different populations of cells in the first module simultaneously with activation, genetic modification and expansion of another of the different populations of cells in the second module.

12 . A bioprocessing system, comprising: a first module configured for enriching and isolating a population of cells; at least two second modules configured for activating, genetically modifying, and expanding an isolated population of cells; a third module configured for harvesting the expanded population of cells; and wherein the first module is configured for enriching a second population of cells while the second module is carrying out activation, genetic modification, and/or expansion on a first population of cells; and wherein after the first module transfers a first population of isolated cells to a first second module of the at least two second modules, the first module prepares and provides for transfer of the second population of isolated cells to a second module while the first second module is activating, genetically modifying, and/or expanding the first population of isolated cells.

13 . The bioprocessing system of claim 12 , further comprising:

wherein the third module is configured for enriching an isolating a population of cells and provides an additional population of isolated cells to at least one additional second module during the operation of at least one of the at least two second modules.

14 . The bioprocessing system of claim 1 , wherein each module further comprises a sterile, closed fluid path with at least one input port and at least one output port, such that the first, second, and third modules are fluidically isolated from each other.

15 . The bioprocessing system of claim 1 , wherein the system is configured for parallel and asynchronous processing of multiple populations of cells.

16 . The bioprocessing system of claim 1 , further comprising an additional second module, wherein the additional second module is configured for activating, genetically modifying, and expanding the second population of cells while the second module is activating, genetically modifying, and expanding the first population of cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: GRIFFIN, WESTON BLAINE; CORWIN, ALEX D; ZHANG, XIAOHUA; SMITH, REGINALD DONOVAN; LIU, ZHEN; ZHANG, CHENGKUN; KESKAR, VANDANA; DAVIS, BRIAN MICHAEL; SHAIKH, KASHAN
To: GENERAL ELECTRIC COMPANY
Reel/Frame 066167/0811 →
CHANGE OF NAME Recorded Jan 18, 2024
From: GENERAL ELECTRIC COMPANY
To: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
Reel/Frame 066168/0415 →
Continuity (10)
Continuation 16968342
Continuation 15893336 · Feb 9, 2018
Provisional Application 62736130 · Sep 25, 2018
Provisional Application 62736144 · Sep 25, 2018
Provisional Application 62736125 · Sep 25, 2018
Provisional Application 62736120 · Sep 25, 2018
Provisional Application 62736154 · Sep 25, 2018
Provisional Application 62736115 · Sep 25, 2018
Provisional Application 62736143 · Sep 25, 2018
Related Publication 20240200012A1 · Jun 20, 2024
References Cited (111)
US 4601730A · Mcgowan et al. · 1986 [cited by applicant]
US 5449617A · Falkenberg et al. · 1995 [cited by applicant]
US 5693537A · Wilson et al. · 1997 [cited by applicant]
US 5726450A · Peterson et al. · 1998 [cited by applicant]
US 7601545B2 · Barringer, Jr. · 2009 [cited by applicant]
US 7745209B2 · Martin et al. · 2010 [cited by applicant]
US 7919307B2 · Klaus et al. · 2011 [cited by applicant]
US 8158427B2 · Wilson et al. · 2012 [cited by applicant]
US 9175253B2 · Hata et al. · 2015 [cited by applicant]
US 9206383B2 · Vunjak-Novakovic et al. · 2015 [cited by applicant]
US 10458920B2 · Planas et al. · 2019 [cited by applicant]
US 10696961B2 · Zhang et al. · 2020 [cited by applicant]
US 11332732B2 · Zhang et al. · 2022 [cited by applicant]
US 11920119B2 · Griffin · 2024 [cited by examiner]
US 20020055166A1 · Cannon et al. · 2002 [cited by applicant]
US 20020146816A1 · Vellinger et al. · 2002 [cited by applicant]
US 20020189374A1 · DeSilets et al. · 2002 [cited by applicant]
US 20040214314A1 · Srienc et al. · 2004 [cited by applicant]
US 20050051723A1 · Neagle et al. · 2005 [cited by applicant]
US 20050180891A1 · Webster et al. · 2005 [cited by applicant]
US 20050230767A1 · Park et al. · 2005 [cited by applicant]
US 20080227190A1 · Antwiler · 2008 [cited by applicant]
US 20100236340A1 · Lee et al. · 2010 [cited by applicant]
US 20110020179A1 · Yue et al. · 2011 [cited by applicant]
US 20110136225A1 · Vunjak-Novakovic et al. · 2011 [cited by applicant]
US 20130157353A1 · Dijkhuizen Borgart et al. · 2013 [cited by applicant]
US 20130206597A1 · Wang et al. · 2013 [cited by applicant]
US 20140335608A1 · Tanaka et al. · 2014 [cited by applicant]
US 20150329815A1 · Wilson et al. · 2015 [cited by applicant]
US 20160340633A1 · Davis et al. · 2016 [cited by applicant]
US 20170253847A1 · Koseki · 2017 [cited by applicant]
US 20200392446A1 · Griffin et al. · 2020 [cited by applicant]
US 20210087510A1 · Griffin et al. · 2021 [cited by applicant]
US 20210102157A1 · Griffin et al. · 2021 [cited by applicant]
AU 2018376657B2 · 2018 [cited by applicant]
CN 1501835A · 2004 [cited by applicant]
CN 101014712A · 2007 [cited by applicant]
CN 102504991 · 2012 [cited by applicant]
CN 104640973A · 2015 [cited by applicant]
CN 105392877A · 2016 [cited by applicant]
CN 106062185A · 2016 [cited by applicant]
CN 106459915A · 2017 [cited by applicant]
CN 106466495A · 2017 [cited by applicant]
EP 1944359 · 2008 [cited by applicant]
EP 3717622A0 · 2018 [cited by applicant]
GB 2268187 · 1994 [cited by applicant]
JP 2002542004 · 2002 [cited by applicant]
JP 2007535965A · 2007 [cited by applicant]
JP 2015221001A · 2015 [cited by applicant]
JP 2016153124 · 2016 [cited by applicant]
JP 2017513499A · 2017 [cited by applicant]
JP 2021512633A · 2021 [cited by applicant]
JP 7350741B2 · 2023 [cited by applicant]
KR 1020080072006A · 2008 [cited by applicant]
KR 1020160145162A · 2016 [cited by applicant]
WO 02070120A1 · 2002 [cited by applicant]
WO 2005108589A1 · 2005 [cited by applicant]
WO 2010040748A1 · 2010 [cited by applicant]
WO 2010062599 · 2010 [cited by applicant]
WO 2010080032A2 · 2010 [cited by applicant]
WO 2012079000A1 · 2012 [cited by applicant]
WO 2014051503A1 · 2014 [cited by applicant]
WO 2015001321A1 · 2015 [cited by applicant]
WO 2015120096A2 · 2015 [cited by applicant]
WO 2015162211A1 · 2015 [cited by applicant]
WO 2016007216A1 · 2016 [cited by applicant]
WO 2016118780 · 2016 [cited by applicant]
WO 2016168687A1 · 2016 [cited by applicant]
WO 2016185221A1 · 2016 [cited by applicant]
WO 2016189159A1 · 2016 [cited by applicant]
WO 2017035262 · 2017 [cited by applicant]
WO 2017190254 · 2017 [cited by applicant]
WO 2018005521 · 2018 [cited by applicant]
WO 2018111931 · 2018 [cited by applicant]
WO 2019106207A1 · 2019 [cited by applicant]
Australian Examination Report dated Nov. 30, 2023 for Application No. 2019219295. [cited by applicant]
English translation of Chinese Office Action dated Dec. 21, 2023 for Application No. 201880088322.2. [cited by applicant]
Australian Examination Report dated Dec. 7, 2023 for Application No. 2019219292. [cited by applicant]
Australian Examination Report dated Nov. 28, 2023 for Application No. 2019219241. [cited by applicant]
Indian Hearing Notice dated Feb. 5, 2024 for Application No. 202017032170. [cited by applicant]
Corresponding Korean Patent Application No. 10-2020-7025578 Office Action dated May 23, 2024. [cited by applicant]
Corresponding Chinese Patent Application No. 201980024222.8 Office Action dated May 29, 2024. [cited by applicant]
Hollyman, Daniel; Title: Manufacturing validation of biologically functional T Cells targeted to CD19 antigen for autologous adoptive cell therapy; Date: Feb. 1, 2010. [cited by applicant]
United States Office Action dated Oct. 30, 2024 for U.S. Appl. No. 16/968,374. [cited by applicant]
Mock et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy Cytotherapy, 2016; 18: 1002-1011. (Year 2016). [cited by applicant]
GE Application note. “Perfucsion culture of T lymphocytes in the WAVE Bioreactor System 2/10 (software version 2.61)”, GE Healthcare Life Sciences, Application note 28-9650-52 AC. Published Jan. 2010, p. 1-9. (Year: 201… [cited by applicant]
Mexico Office Action dated Aug. 22, 2024 for Application No. MX/a/2020/008317. [cited by applicant]
Korea Office Action dated Sep. 5, 2024 for Application No. 10-2020-7018529. [cited by applicant]
Canadian Examiners Report for corresponding Canada Application No. 3082861, dated Mar. 11, 2025, 6 pages. [cited by applicant]
Singh, V., “Disposable bioreactor for cell culture using wave-induced agitation”, Cytotechnology vol. 30, Year: 1999, pp. 149-158. [cited by applicant]
Japanese Office Action for corresponding Japan Application No. 2023-215870, dated Feb. 18, 2025, 5 pages. [cited by applicant]
Canadian Office Action in Canadian Application No. 3,090,047, mailed Jun. 20, 2025, 4 pages. [cited by applicant]
“For Increasing Efficiency in Gene Transfer Using Retrovirus/Lentivirus Vectors! RetroNectin,” 2021, https://catalog.takara-bio.co.jp/PDFS/retronectin_201601.pdf, 2 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/078,157 mailed Sep. 19, 2025, 21 pages. [cited by applicant]
Second Japanese Office Action for Japanese Application No. 2023-215870, mailed Sep. 2, 2025, 1 pages. [cited by applicant]
Canadian Office Action for Canadian Application No. 3,089,788, mailed Aug. 15, 2025, 6 pages. [cited by applicant]
First Office Action issued in China application No. 201980024225.1, dated Sep. 1, 2023 (18 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,333, dated Sep. 20, 2023 (8 pages). [cited by applicant]
First Office Action issued in China application No. 201980024234.0, dated Aug. 29, 2023 (15 pages). [cited by applicant]
First Office Action issued in China application No. 201980024224.7, dated Aug. 31, 2023 (22 pages). [cited by applicant]
First Office Action issued in China application No. 201980024223.2, dated Aug. 16, 2023 (24 pages). [cited by applicant]
First Office Action issued in China application No. 201980024235.5, dated Aug. 30, 2023 (15 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,374, dated Jan. 17, 2024 (46 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,315, dated Jan. 17, 2024, 28 pages. [cited by applicant]
Examination Report issued in Australian Application No. 2019219241, dated Nov. 28, 2023, 3 pages. [cited by applicant]
Office Action in Chinese Application No. 201980024013.3, dated May 1, 2024, 9 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 17/734,562, dated Feb. 26, 2024, 14 pages. [cited by applicant]
Office Action issued in KR Application No. 10-2020-7018529, mailed Sep. 13, 2024, 13 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/968,304, mailed Dec. 19, 2024, 15 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 18/400,052, mailed May 21, 2025, 13 pages. [cited by applicant]
Office Action issued in AU Application No. 2019219291, mailed Sep. 11, 2024, 3 pages. [cited by applicant]